Abstract 1564P
Background
With over 2 million cases diagnosed annually, breast cancer is a leading cause of cancer-related disability and mortality worldwide. Despite global efforts to implement screening programs, uptake rates vary widely across settings due to socioeconomic factors and accessibility challenges. In 2022 in Flanders (Belgium), breast cancer screening participation in municipalities with income below the poverty line was 15% lower than average.
Methods
To tackle the limited participation of low-SES women in the breast cancer screening program in Flanders, a culturally sensitive approach was used to realize a tailored reminder letter.
33 women (of which 29 non-native Dutch speakers) aged 50-69 with low-SES were identified with the assistance of community organizations to conduct Focus Group Discussions (FGDs). Through a series of 4 FGDs and 3 rounds of Delphi-consultations involving sector experts, valuable insights were gathered.
Results
Analysis of the standard invitation letter employed in the program revealed several challenges related to readability and comprehension. These included the excessive length of the text, the use of complex vocabulary and grammar beyond an A2 level, the inclusion of contextual sentences unrelated to the mammography appointment (“We do it. And what do you do?”), and the use of generic visuals (eg. a picture of women).
At the same time, simplifying the vocabulary to A1-A2 levels (“cancer”, “doctor”, “appointment”, “check”, “free”), employing straightforward sentence structures, and incorporating relevant visuals (e.g. image of a mammography machine) enhanced understandability and fostered interest in breast cancer prevention. Additionally, utilizing a color palette associated with breast cancer and featuring logos of local authorities instilled a sense of credibility and trustworthiness.
Conclusions
Based on feedback from sector experts and insights from the FGDs, a revised reminder letter was developed. The final communication was concise and included essential details such as time and place for screening, as well as a QR code providing translation into 12 languages.
To assess its efficacy in increasing participation rates, a RCT with 3,430 participants per arm is currently being conducted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Stichting tegen Kanker.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1574P - Medical oncology residents mentors (MORM): A target for resiliency interventions
Presenter: David Paez
Session: Poster session 10
1575P - Smoke-free policies in outdoor areas: A potential cancer prevention strategy in Spain
Presenter: Karen Ramírez Cervantes
Session: Poster session 10
1576P - Smoking and lung cancer mortality in Italian men and women: 2003-2019
Presenter: Diego Serraino
Session: Poster session 10
1577P - Indoor radon in patients with lung cancer in Spain: Preliminary data from the MIRROR study
Presenter: Marta Garcia De Herreros
Session: Poster session 10
1578P - Perception of LMIC oncologists on meaningful cancer trial endpoints and value of cancer drugs
Presenter: Soumitra Shankar Datta
Session: Poster session 10
1579P - The Dutch national adolescent and young adult (AYA) cancer care network, a data driven learning healthcare system
Presenter: Winette Van Der Graaf
Session: Poster session 10
1580P - Impact of social determinants of health (SDOH) on disparities in next-generation sequencing (NGS) testing in cancer patients (pts) in the US
Presenter: Chadi Hage Chehade
Session: Poster session 10
1581P - AI enabled intervention increased real-world guideline compliant care: Improving genomic testing and cascade genetics for women with ovarian cancer (OC)
Presenter: Premal Thaker
Session: Poster session 10
1582P - Pregnancy and miscarriage in epithelial ovarian cancer (EOC) patients harboring mutational signature of homologous recombination deficiency (HRD)
Presenter: Lorena Incorvaia
Session: Poster session 10
1583P - Trial-level surrogacy of intermediate endpoints in adjuvant or neoadjuvant use of immune checkpoint blockade
Presenter: Luís Leite
Session: Poster session 10